Dayton Clinical Oncology Program

代顿临床肿瘤学项目(代顿NCORP)：项目摘要/摘要 代顿临床肿瘤学计划，以下简称“代顿NCORP”，被纳入 俄亥俄州在1983年作为一个非营利性的501C3公司，和最初的NCI社区之一 临床肿瘤学计划(CCOP)。当时，双方达成了一项财团协议。 代顿NCORP、代顿地区成人医院和莱特州立大学(WSU)。治国之道 成立了董事会，制定了公司章程。 凯特琳医疗中心一直是最初的受资助组织，直到2001年，代顿NCORP 与WSU签订了人力资源、技术支持和财务监督的分包合同。代顿 NCORP与当地一家会计师事务所签订合同，进行A-133年度外部财务审计。在……里面 2014年，代顿临床肿瘤学项目成功获得NCI社区肿瘤学奖 研究计划(NCORP)社区站点五年补助金。 目前，代顿NCORP董事会由首席调查员霍华德·M·格罗斯领导， 医学博士担任主席，副首席调查员兼委员会副主席John Haluschak博士 董事会主席兼首席执行官Mary Ontko，BSN，RN，OCN。其他 董事代表财团医院成员。董事会每半年召开一次会议，审查预算 报告和计划活动。 54名医生，代表内科、外科、妇科肿瘤学和放射治疗，20 以医院为基础的肿瘤研究护士，由我们的成员医院资助，13名办公室工作人员，资助 根据NCI的拨款，组成研究团队。办公室工作人员包括质量、监管、 和研究项目，以及研究协调员、药房技术员、行政管理人员 专家，还有一名助理研究员。代顿NCORP正在扩张；位于扬斯敦的三家医院 俄亥俄州东北部已经签署了财团协议，并正在进行这一进程的第一步 加入代顿NCORP等网站都表示有兴趣加入。 代顿NCORP目前正在寻求在截至8月的六年赠款期间继续提供资金 2019年7月1日至2025年7月31日。继续提供资金将使该财团能够继续代顿 NCORP使命通过改进治疗和预防来降低癌症发病率和死亡率 通过向当地社区提供国家最先进的癌症研究。

Dayton Clinical Oncology Program (Dayton NCORP): Project Summary/Abstract The Dayton Clinical Oncology Program, hereafter referred to as “Dayton NCORP”, was incorporated in the State of Ohio in 1983 as a non-profit 501c3 corporation, and one of the original NCI Community Clinical Oncology Programs (CCOP). At that time, a consortium agreement was established between Dayton NCORP, the Dayton area adult hospitals, and Wright State University (WSU). A governing board was established and corporate bylaws were developed. Kettering Medical Center was the original grantee organization until 2001, when Dayton NCORP subcontracted with WSU for human resources, technical support, and financial oversight. Dayton NCORP contracts with a local accounting firm to conduct an annual external A-133 financial audit. In 2014, Dayton Clinical Oncology Program, was successfully awarded an NCI Community Oncology Research Program (NCORP) Community Site five-year grant. Currently, the Dayton NCORP Board of Directors is led by Principal Investigator Howard M. Gross, M.D. as Chairperson, Dr. John Haluschak, Associate Principal Investigator and Vice Chairperson of the Board, and Mary Ontko, BSN, RN, OCN, President of the Board and Chief Executive Officer. Other directors represent consortium hospital-members. The Board meets semi-annually to review budget reports and program activities. Fifty-four physicians, representing medical, surgical, gynecological oncology and radiation therapy, 20 hospital-based oncology research nurses, funded by our member hospitals, and 13 office staff, funded by the NCI grant, make up the research team. The office staff includes directors for quality, regulatory, and research projects, along with research coordinators, a pharmacy technician, an administrative specialist, and a research associate. Dayton NCORP is expanding; three hospitals in Youngstown, in northeast Ohio, have signed a Consortium Agreement and are undergoing the first steps of the process to join Dayton NCORP, and other sites have expressed interest in joining. Dayton NCORP is currently seeking continued funding through the six-grant year period running August 1, 2019 through July 31, 2025. Continued funding will allow the consortium to continue the Dayton NCORP mission To reduce cancer incidence and mortality through improved treatment and prevention by offering national state-of-the-art cancer research to the local communities.